Back to top
more

Oncolytics Biotech (ONCY)

(Delayed Data from NSDQ)

$0.86 USD

0.86
987,402

-0.06 (-6.20%)

Updated Aug 8, 2025 04:00 PM ET

After-Market: $0.86 0.00 (0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 244)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Oncolytics Biotech (ONCY) Loses -9.34% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

by Zacks Equity Research

Oncolytics Biotech (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Oncolytics Biotech (ONCY) Upgraded to Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Oncolytics Biotech (ONCY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

ONCY Stock Up on Regulatory Update From Breast Cancer Program

by Zacks Equity Research

Oncolytics stock soars as the company seeks an accelerated approval pathway for its lead candidate, pelareorep, to treat a breast cancer indication.

Zacks Equity Research

Oncolytics Biotech (ONCY) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

by Zacks Equity Research

Oncolytics Biotech (ONCY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks Equity Research

Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect?

by Zacks Equity Research

Investors' focus is likely to be on Gilead's (GILD) HIV franchise performance and oncology sales when the company reports first-quarter 2024 results.

Zacks Equity Research

Bristol-Myers' (BMY) to Report Q1 Earnings: What You Should Know

by Zacks Equity Research

Investors are likely to focus on Opdivo's demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) posts Q1 results.

Ekta Bagri headshot

Novartis (NVS) to Report Q1 Earnings: What to Expect?

by Ekta Bagri

Novartis (NVS) key drugs Entresto, Kisqali and Pluvicto are likely to have fueled its top and bottom-line numbers in the first quarter.

Zacks Equity Research

After Plunging -29.54% in 4 Weeks, Here's Why the Trend Might Reverse for Oncolytics Biotech Inc. (ONCY)

by Zacks Equity Research

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

New Strong Buy Stocks for January 18th

by Zacks Equity Research

DTEGY, CYN, OKTA, HOWL and ONCY have been added to the Zacks Rank #1 (Strong Buy) List on January 18, 2022.

Zacks Equity Research

Is DICE Therapeutics (DICE) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how DICE Therapeutics, Inc. (DICE) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Sanghamitra Saha headshot

2 Sector ETFs Hovering Around a 52-Week High

by Sanghamitra Saha

We all know that Wall Street is shattered this year. Still, two sectors -- Biotech and Aerospace -- have recently hit a 52-week high.

Zacks Equity Research

What Makes Oncolytics Biotech Inc. (ONCY) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research

Does Oncolytics Biotech Inc. (ONCY) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Equity Research

Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag

by Zacks Equity Research

Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.

Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Is Olink Holding (OLK) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Olink Holding AB publ Sponsored ADR (OLK) and Oncolytics Biotech Inc. (ONCY) have performed compared to their sector so far this year.

Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

by Zacks Equity Research

After losing some value lately, a hammer chart pattern has been formed for Oncolytics Biotech Inc. (ONCY), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Zacks Equity Research

Zacks.com featured highlights include Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics and Oncolytics Biotech

by Zacks Equity Research

Boot Barn, Canada Goose, Pediatrix Medical Group, Leap Therapeutics, and Oncolytics Biotech are part of Zacks Screen of the week article.

Sanghamitra Saha headshot

Ride on Rising P/E Investing With These 5 Top-Ranked Stocks

by Sanghamitra Saha

Want to try an out-of-the-box approach? Tap Oncolytics Biotech (ONCY), Pediatrix Medical Group Inc (MD), Boot Barn (BOOT), Canada Goose (GOOS) and Leap Therapeutics (LPTX).

Zacks Equity Research

Oncolytics Biotech (ONCY) Sees Hammer Chart Pattern: Time to Buy?

by Zacks Equity Research

Oncolytics Biotech (ONCY) has been struggling lately, but the selling pressure may be coming to an end soon.

Zacks Equity Research

Here's Why Oncolytics Biotech Inc. (ONCY) Could be Great Choice for a Bottom Fisher

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Sanghamitra Saha headshot

5 Stocks With Rising P/E Are Good Buys

by Sanghamitra Saha

Bet on top-ranked stocks STKL, LZB, ONCY, TPR and TRVI that have rising P/E to realize outsized gains.

Zacks Equity Research

Down 23.9% in 4 Weeks, Here's Why You Should You Buy the Dip in Oncolytics Biotech Inc. (ONCY)

by Zacks Equity Research

Oncolytics Biotech Inc. (ONCY) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks Equity Research

Here's Why Oncolytics Biotech Inc. (ONCY) is Poised for a Turnaround After Losing 19.6% in 4 Weeks

by Zacks Equity Research

The heavy selling pressure might have exhausted for Oncolytics Biotech Inc. (ONCY) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Zacks Equity Research

Oncolytics Biotech (ONCY) Enters Overbought Territory

by Zacks Equity Research

Oncolytics Biotech (ONCY) has moved higher as of late, but there could definitely be trouble on the horizon for this company

Tirthankar Chakraborty headshot

New Strong Buy Stocks For May 28th

by Tirthankar Chakraborty

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List today: